Standard Safety Procedure Before Therapeutic Administration of 223Ra-Dichloride.
J Nucl Med Technol
; 52(3): 219-220, 2024 Sep 05.
Article
em En
| MEDLINE
| ID: mdl-39237342
ABSTRACT
223Ra-dichloride is an α-emitter therapy approved for the treatment of castration-resistant prostate cancer with symptomatic bone metastases. 223Ra-dichloride is the first targeted α-therapy for this indication with evidence of benefit in overall survival. The administration is intravenous, and extravasation can cause severe injuries such as tissue necrosis. To prevent this side effect, some procedures can be performed according to the guideline of the European Association of Nuclear Medicine. Ionizing radiation is a well-established risk factor for the development of cutaneous squamous cell carcinoma, but surprisingly there are few reports of local adverse effects related to extravasation of radiotherapies at the injection sites. Recently, a possible case of cutaneous cancer was observed after 223Ra-dichloride extravasation. Methods:
To complement the prevention of extravasation, we developed a standardized technique to be performed before the injection of 223Ra.Results:
Our technique was successfully applied to the study population, and no apparent extravasation was seen.Conclusion:
Our study suggests that use of this standardized technique before administration of 223Ra is helpful in preventing extravasation during this treatment.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Rádio (Elemento)
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
J Nucl Med Technol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Estados Unidos